353 related articles for article (PubMed ID: 15555548)
21. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
Shi RX; Ong CN; Shen HM
Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
[TBL] [Abstract][Full Text] [Related]
22. Adenovirus-mediated gene transfer of caspase-8 sensitizes human adenocarcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand.
Yasui H; Adachi M; Hamada H; Imai K
Int J Oncol; 2005 Feb; 26(2):537-44. PubMed ID: 15645141
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL).
Routes JM; Ryan S; Clase A; Miura T; Kuhl A; Potter TA; Cook JL
J Immunol; 2000 Oct; 165(8):4522-7. PubMed ID: 11035092
[TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
[TBL] [Abstract][Full Text] [Related]
25. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice.
Ishikawa E; Nakazawa M; Yoshinari M; Minami M
J Virol; 2005 Jun; 79(12):7658-63. PubMed ID: 15919918
[TBL] [Abstract][Full Text] [Related]
26. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
Bernt KM; Ni S; Tieu AT; Lieber A
Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
[TBL] [Abstract][Full Text] [Related]
28. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.
Armeanu S; Lauer UM; Smirnow I; Schenk M; Weiss TS; Gregor M; Bitzer M
Cancer Res; 2003 May; 63(10):2369-72. PubMed ID: 12750253
[TBL] [Abstract][Full Text] [Related]
29. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
Panichakul T; Intachote P; Wongkajorsilp A; Sripa B; Sirisinha S
Anticancer Res; 2006; 26(1A):259-65. PubMed ID: 16475706
[TBL] [Abstract][Full Text] [Related]
30. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Liu J; Fang B
Int J Oncol; 2003 Jun; 22(6):1241-5. PubMed ID: 12738989
[TBL] [Abstract][Full Text] [Related]
31. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
32. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.
Van Geelen CM; de Vries EG; de Jong S
Drug Resist Updat; 2004 Dec; 7(6):345-58. PubMed ID: 15790545
[TBL] [Abstract][Full Text] [Related]
33. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
34. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
35. Potential and caveats of TRAIL in cancer therapy.
Held J; Schulze-Osthoff K
Drug Resist Updat; 2001 Aug; 4(4):243-52. PubMed ID: 11991679
[TBL] [Abstract][Full Text] [Related]
36. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
37. [Tumor necrosis factor related apoptosis-inducing ligand induces apoptosis and sensitizes resistant hepatic cancer cells to chemotherapy].
He SQ; Chen XP; Zhang WG; Wang HP; Wang Q
Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):456-9. PubMed ID: 15329202
[TBL] [Abstract][Full Text] [Related]
38. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
40. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
Kang J; Bu J; Hao Y; Chen F
Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]